 Marc Mathias
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 14 | 2025 | 190 | 2.170 |
Why?
| | Geographic Atrophy | 8 | 2025 | 97 | 1.340 |
Why?
| | Visual Acuity | 10 | 2025 | 491 | 0.850 |
Why?
| | Wet Macular Degeneration | 4 | 2025 | 58 | 0.650 |
Why?
| | Tomography, Optical Coherence | 7 | 2025 | 270 | 0.510 |
Why?
| | Retinal Drusen | 3 | 2021 | 31 | 0.490 |
Why?
| | Eye Infections, Bacterial | 2 | 2015 | 45 | 0.450 |
Why?
| | Registries | 6 | 2025 | 2392 | 0.410 |
Why?
| | Fluorescein Angiography | 5 | 2025 | 190 | 0.380 |
Why?
| | Orbital Cellulitis | 1 | 2012 | 17 | 0.350 |
Why?
| | Complement Activation | 3 | 2025 | 409 | 0.340 |
Why?
| | Endophthalmitis | 3 | 2017 | 46 | 0.340 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Choroid | 3 | 2025 | 80 | 0.290 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 248 | 0.280 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 388 | 0.260 |
Why?
| | Choroid Diseases | 2 | 2023 | 10 | 0.230 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.230 |
Why?
| | Vitreous Body | 2 | 2015 | 117 | 0.210 |
Why?
| | Diseases in Twins | 1 | 2024 | 115 | 0.210 |
Why?
| | Twins | 1 | 2024 | 152 | 0.200 |
Why?
| | Retinal Degeneration | 1 | 2023 | 39 | 0.190 |
Why?
| | Retinopathy of Prematurity | 1 | 2024 | 180 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 314 | 0.180 |
Why?
| | Vitrectomy | 3 | 2025 | 73 | 0.180 |
Why?
| | Birth Weight | 1 | 2024 | 506 | 0.170 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 150 | 0.150 |
Why?
| | Aged, 80 and over | 8 | 2025 | 8284 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 143 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.140 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5414 | 0.140 |
Why?
| | Internet | 1 | 2023 | 698 | 0.140 |
Why?
| | Aged | 13 | 2025 | 25955 | 0.130 |
Why?
| | Anterior Eye Segment | 1 | 2017 | 10 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6041 | 0.120 |
Why?
| | Female | 19 | 2025 | 78304 | 0.120 |
Why?
| | Strabismus | 1 | 2017 | 71 | 0.120 |
Why?
| | Automobile Driving | 1 | 2018 | 157 | 0.120 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2017 | 90 | 0.120 |
Why?
| | Humans | 26 | 2025 | 144671 | 0.120 |
Why?
| | Retinal Vein Occlusion | 1 | 2015 | 14 | 0.110 |
Why?
| | Male | 16 | 2025 | 72431 | 0.110 |
Why?
| | Needles | 1 | 2015 | 62 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2025 | 17149 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2015 | 184 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 869 | 0.100 |
Why?
| | Fibrin | 1 | 2014 | 84 | 0.100 |
Why?
| | Ischemia | 1 | 2017 | 422 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2015 | 238 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1129 | 0.090 |
Why?
| | Retina | 1 | 2015 | 319 | 0.090 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 199 | 0.090 |
Why?
| | Eyelid Diseases | 1 | 2012 | 26 | 0.090 |
Why?
| | Ocular Motility Disorders | 1 | 2012 | 42 | 0.090 |
Why?
| | Edema | 1 | 2012 | 124 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5870 | 0.080 |
Why?
| | Biomarkers | 4 | 2023 | 4261 | 0.080 |
Why?
| | Atrophy | 2 | 2023 | 199 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 990 | 0.070 |
Why?
| | Time Factors | 3 | 2025 | 7140 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 894 | 0.070 |
Why?
| | Middle Aged | 7 | 2025 | 35971 | 0.060 |
Why?
| | Odds Ratio | 2 | 2019 | 1076 | 0.060 |
Why?
| | Colorado | 3 | 2022 | 4558 | 0.060 |
Why?
| | Fundus Oculi | 1 | 2025 | 89 | 0.060 |
Why?
| | Quality of Life | 3 | 2022 | 3183 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2015 | 1928 | 0.060 |
Why?
| | Risk Factors | 3 | 2025 | 10796 | 0.050 |
Why?
| | Infant | 2 | 2025 | 10023 | 0.050 |
Why?
| | Child, Preschool | 2 | 2025 | 11790 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 206 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3147 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2950 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2754 | 0.040 |
Why?
| | Gestational Age | 1 | 2024 | 980 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 115 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 181 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 179 | 0.040 |
Why?
| | Inflammation | 2 | 2023 | 2870 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 259 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Adolescent | 2 | 2025 | 22409 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3888 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 420 | 0.040 |
Why?
| | Child | 2 | 2025 | 22600 | 0.040 |
Why?
| | Prospective Studies | 2 | 2020 | 7994 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2847 | 0.030 |
Why?
| | Iris Diseases | 1 | 2017 | 7 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 477 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 835 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 776 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 792 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 34 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 123 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1537 | 0.030 |
Why?
| | Young Adult | 1 | 2012 | 14122 | 0.030 |
Why?
| | Intravitreal Injections | 1 | 2015 | 71 | 0.030 |
Why?
| | Macular Edema | 1 | 2015 | 49 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 2114 | 0.030 |
Why?
| | Bevacizumab | 1 | 2015 | 168 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1016 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1183 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1984 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6399 | 0.020 |
Why?
| | Adult | 2 | 2015 | 40489 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 550 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3603 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5957 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1811 | 0.020 |
Why?
| | United States | 1 | 2020 | 16018 | 0.010 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|